In the Claims:

Amend claim 1 to recite the wording stated below.

Also, in accordance with the requirements of the revised amendment format for 37 C.F.R. 1.121 (mandatory as of July 30, 2003), applicant presents below the text of all the presently allowed claims in the instant application. Accordingly, the full text for each of pending claims 1, 4-11, and 15 respectively is set forth below, starting on the immediately following page.

1 (Currently Amended). A genetically modified human microglia cell which can be maintained as a stable, substantially homogeneous cell line in-vitro, said genetically modified cell comprising:

a microglia cell of human origin which is stable when maintained in culture and which

(i) has demonstrable phagocytic properties;

(ii) produces substantially homogenous progeny continuously while maintained in culture;

(iii) presents at least CD11b and CD68 as surface antigens; and

(iv) contains human genomic DNA which has been genetically modified to include a viral vector carrying at least one DNA segment encoding an exogenous gene for intracellular expression wherein said viral vector is an amphotrophic retroviral vector and wherein said viral vector includes ~~as~~ an exogeneous DNA sequence encoding a v-myc gene.

2 (Cancelled).

3 (Cancelled).

4 (Previously Amended). The genetically modified human microglia cell as recited in claim 1 further comprising the presence of the surface antigen RcA-lectin;

5 (Original). The genetically modified human microglia cell as recited in claim 1 further comprising the presence of $P_{2Y1}$ receptors.

6 (Previously Amended). The genetically modified human microglia cell as recited in claim 1 further comprising the presence of the surface antigens HLA-ABC (MHC class I), and HLA-DR (MHC class II).

7 (Original). The genetically modified human microglia cell as recited in claim 1 wherein said cell expresses at least one active substance selected from the group consisting of cytokines and chemokines.

8 (Previously Amended). The genetically modified human microglia cell as recited in claim 7 wherein said expressed active substance is selected from the group consisting of MIP-1β, MCP-1, IL-1β, IL-6, IL-8, IL-12, and IL-15.

9 (Original). The genetically modified human microglia cell as recited in claim 1 wherein said cell is in a non-stimulated state.

10 (Original). The genetically modified human microglia cell as recited in claim 1 wherein said cell is in a stimulated state.

11 (Previously Amended). The genetically modified human microglia cell as recited in claim 10 wherein said stimulated cell overexpresses at least one pharmacologically active substance selected from the group consisting of cytokines and chemokines.

12 (Cancelled).

13 (Cancelled).

14 (Cancelled).

15 (Previously Amended). A method for transforming human microglial cells into a genetically modified microglial cell line of claim 1, said method comprising

(a) obtaining human microglial cells;

(b) culturing said human microglial cells;

(c) transfecting said cultured human microglial cells using an amphotrophic replication incompetent retroviral vector encoding a v-myc oncogene; and

(d) expanding said transfectants in culture media as an immortalized, substantially homogeneous cell line.

16 (Cancelled).

17 (Cancelled).

18 (Cancelled).

19 (Cancelled).